Kalaris Therapeutics Reports Q2 2026 Financial Results

What Happened
Kalaris Therapeutics, Inc. announced its financial results for the quarter ended June 30, 2026 via a press release dated August 11, 2026. The company furnished that press release on Form 8-K under Item 2.02 (Results of Operations and Financial Condition).

Key Details

• Form 8-K furnished on August 11, 2026 announcing quarterly results for the period ended June 30, 2026.
• Press release is attached as Exhibit 99.1 to the Current Report on Form 8-K.
• The Form 8-K states the information is being furnished (not “filed”) and therefore is not subject to Section 18 liability under the Exchange Act.
• The filing includes the Inline XBRL cover page (Exhibit 104).

Why It Matters
This filing signals that Kalaris has publicly released its latest quarterly financial performance; investors should review the attached press release for revenue, expenses, cash position, guidance, or other operating metrics that could affect the stock. Note that the company treated the release as “furnished” rather than “filed,” which has limited legal implications for liability under the Exchange Act. For full financial detail and any presented metrics, consult the Exhibit 99.1 press release and the company’s periodic SEC filings.